Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

This was the stock's third consecutive day of gains.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...